Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Audio By Carbonatix

PALO ALTO, Calif.--(BUSINESS WIRE)--Aug 26, 2025--

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.

Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 8 th at 4:05 p.m. ET. Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250826700094/en/

CONTACT: Investor Contact:

Zarak Khurshid

[email protected] Contact:

Meaghan Smith

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: ONCOLOGY HEALTH HEALTH TECHNOLOGY GENERAL HEALTH RESEARCH SCIENCE

SOURCE: Guardant Health, Inc.

Copyright Business Wire 2025.

PUB: 08/26/2025 04:05 PM/DISC: 08/26/2025 04:06 PM

http://www.businesswire.com/news/home/20250826700094/en